ImmunityBio’s Patrick Soon-Shiong Discusses Quest to Orchestrate NK and T Cells

Three decades after first writing about how natural killer cells (NK) functioned, Dr. Patrick Soon-Shiong, M.D., and his company, ImmunityBio, Inc. are on the final leg of what they hope will be U.S. Food and Drug Administration approval of their drug, N-803 (anktiva), for the treatment of bladder cancer.